Halozyme Reports Second Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Halozyme Therapeutics (HALO) PT Raised to $66 at BMO Capital
August 10, 2021 9:04 AM EDTBMO Capital analyst Do Kim raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $66.00 (from $64.00) while maintaining an Outperform rating.
The analyst commented, "HALO reported 2Q21 royalty revenues of $45.8mn, ahead of our $40.9mn estimate and consensus' $45.4mn. 2021 guidance was also revised... More
Halozyme Therapeutics (HALO) Tops Q2 EPS by 26c; Raises Outlook
August 9, 2021 4:05 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.66, $0.26 better than the analyst estimate of $0.40. Revenue for the quarter came in at $136.5 million versus the consensus estimate of $103.16 million.
GUIDANCE:
Halozyme Therapeutics sees FY2021 EPS of $1.85-$2.00, versus the consensus of $1.41.... More
